THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER

The University of Texas MD Anderson Cancer Center specializes in preclinical and translational cancer research, with deep expertise in biotechnology development, animal model systems, and biomarker discovery. Their core capabilities include designing and executing preclinical drug efficacy studies, developing iPSC-based cancer vaccines, and advancing immunoprevention strategies targeting receptors such as A2B adenosine. They operate sophisticated non-human primate and small animal colonies under SPF conditions, providing critical in vivo models for oncology research, including per diem care, diagnostic testing, and colony management. Their technical proficiency spans molecular oncology, immunotherapy, metabolic interventions like time-restricted feeding, and intermediate endpoint biomarker validation, positioning them as a leading academic research entity in cancer prevention and therapeutic development. The organization maintains a consistent, long-standing relationship with the Department of Health and Human Services, primarily supporting NIH and NIAID initiatives through biotechnology R&D and animal production services. They also deliver specialized medical physics peer review services to the Department of Veterans Affairs, demonstrating adaptability across clinical and research domains within federal health missions. Their industry focus centers on biotechnology research and life sciences R&D, with a dominant emphasis on cancer-specific applications. They are uniquely positioned as a high-capacity, mission-driven research hub that bridges laboratory discovery with translational readiness, serving as a critical node in the federal cancer research ecosystem. Their work in animal production supports infectious disease and oncology studies, reinforcing their role in end-to-end preclinical development pipelines. As a non-profit academic medical center headquartered in Houston, Texas, the organization operates under a 2A entity structure with no federal certifications. Their government market presence is defined by scientific rigor, regulatory compliance in animal research, and sustained engagement with HHS-led cancer initiatives, making them a trusted partner in federally funded biomedical innovation.